临床试验/NCT01720849

NCT01720849Unknown不适用

Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

Vestre Viken Hospital Trust1 个研究点分布在 1 个国家目标入组 50 人开始时间: 2012年12月最近更新: 2015年6月30日

适应症

干预措施

试验速览

阶段: 不适用
发起方: Vestre Viken Hospital Trust
入组人数: 50
试验地点: 1
主要终点: change from baseline in visual evoked potential after 2 weeks and 3 months

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•All patients who according to the compound's Norwegian prescription guidelines are deemed eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS 4-
•They do not need a past history of optic neuritis, cognitive failure, fatigue or difficulties micturating.

排除标准

•MS patients with contraindications to the compound according to the prescription guidelines.
•Patients who have been exposed to Fampyra in the past Patients with an MS attack within last 3 months

研究组 & 干预措施

Fampyra group

干预措施: Fampyra (Drug)

结局指标

主要结局

change from baseline in visual evoked potential after 2 weeks and 3 months

时间窗: 5 months

次要结局

未报告次要终点

研究者

发起方

Vestre Viken Hospital Trust

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

2 期

Short and Long Term Treatment With 4-AP in Ambulatory SMA PatientsSpinal Muscular Atrophy

NCT01645787Columbia University11

已完成

不适用

Dalfampridine and Gait in Spinocerebellar AtaxiasSpinocerebellar Ataxias Type 1Spinocerebellar Ataxias Type 2Spinocerebellar Ataxias Type 3Spinocerebellar Ataxias Type 6

NCT01811706University of Florida20

已完成

1 期

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseParkinson's Disease

NCT01491022University of Miami22

已完成

不适用

Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life AnalysisMultiple Sclerosis

NCT03164018Genesis Pharma CNS & Specialty111

已完成

2 期

Does Fampridine improve fatigue in patients with Multiple Sclerosis.

ACTRN12611000799954niveristy of New South Wales25